ARTICLE | Clinical News
ASM8: Phase IIa data
March 22, 2010 7:00 AM UTC
In the open-label, Canadian Phase IIa TPI ASM8-206 trial in 12 patients, inhaled 8 mg ASM8 once daily for 4 days met the primary endpoint of significantly reducing sputum eosinophil count at 7 and 24 ...